Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Share-based Compensation: 2021-2024

Historic Share-based Compensation for NewAmsterdam Pharma Co N.V (NAMS) over the last 4 years, with Dec 2024 value amounting to $33.6 million.

  • NewAmsterdam Pharma Co N.V's Share-based Compensation rose 87.72% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year increase of 81.45%. This contributed to the annual value of $33.6 million for FY2024, which is 36.82% up from last year.
  • As of FY2024, NewAmsterdam Pharma Co N.V's Share-based Compensation stood at $33.6 million, which was up 36.82% from $24.6 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's Share-based Compensation's 5-year high stood at $33.6 million during FY2024, with a 5-year trough of $1.2 million in FY2021.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's Share-based Compensation had a median value of $24.6 million in 2023 and averaged $20.8 million.
  • Data for NewAmsterdam Pharma Co N.V's Share-based Compensation shows a peak YoY spiked of 496.84% (in 2023) over the last 5 years.
  • NewAmsterdam Pharma Co N.V's Share-based Compensation (Yearly) stood at $1.2 million in 2021, then surged by 230.95% to $4.1 million in 2022, then soared by 496.84% to $24.6 million in 2023, then skyrocketed by 36.82% to $33.6 million in 2024.